Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ContraFect

DB:22R
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
22R
DB
$84M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • ContraFect has significant price volatility in the past 3 months.
22R Share Price and Events
7 Day Returns
-2.6%
DB:22R
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-19%
DB:22R
-7.4%
DE Biotechs
-14.2%
DE Market
22R Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ContraFect (22R) -2.6% -35.6% -36.9% -19% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 22R underperformed the Biotechs industry which returned -7.4% over the past year.
  • 22R underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
22R
Industry
5yr Volatility vs Market
Related Companies

Value

 Is ContraFect undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ContraFect. This is due to cash flow or dividend data being unavailable. The share price is €4.86.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ContraFect's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ContraFect's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:22R PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.54
NasdaqCM:CFRX Share Price ** NasdaqCM (2020-04-08) in USD $5.5
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ContraFect.

DB:22R PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CFRX Share Price ÷ EPS (both in USD)

= 5.5 ÷ -1.54

-3.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContraFect is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ContraFect is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ContraFect's expected growth come at a high price?
Raw Data
DB:22R PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
44.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ContraFect, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ContraFect's assets?
Raw Data
DB:22R PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.01
NasdaqCM:CFRX Share Price * NasdaqCM (2020-04-08) in USD $5.5
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:22R PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CFRX Share Price ÷ Book Value per Share (both in USD)

= 5.5 ÷ 1.01

5.42x

* Primary Listing of ContraFect.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContraFect is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ContraFect's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ContraFect has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ContraFect expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ContraFect expected to grow at an attractive rate?
  • ContraFect's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • ContraFect's earnings growth is expected to exceed the Germany market average.
  • Unable to compare ContraFect's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:22R Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:22R Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 44.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:22R Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:22R Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 305 195 1
2023-12-31 144 59 1
2022-12-31 0 -36 2
2021-12-31 0 -32 2
2020-12-31 0 -31 4
2020-04-08
DB:22R Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -27 -13
2019-09-30 -27 3
2019-06-30 -29 4
2019-03-31 -27 -7
2018-12-31 -26 -38
2018-09-30 -25 -48
2018-06-30 -25 -46
2018-03-31 -25 -28
2017-12-31 -25 -16
2017-09-30 -27 -10
2017-06-30 -29 -19
2017-03-31 -29 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ContraFect's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if ContraFect is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:22R Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from ContraFect Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22R Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 7.30 7.30 7.30 1.00
2023-12-31 2.24 2.24 2.24 1.00
2022-12-31 -1.47 -1.36 -1.57 2.00
2021-12-31 -1.58 -1.43 -1.72 2.00
2020-12-31 -2.63 -1.90 -3.71 4.00
2020-04-08
DB:22R Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.54
2019-09-30 0.44
2019-06-30 0.57
2019-03-31 -0.90
2018-12-31 -4.95
2018-09-30 -6.48
2018-06-30 -6.37
2018-03-31 -4.45
2017-12-31 -2.79
2017-09-30 -2.14
2017-06-30 -4.71
2017-03-31 -7.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ContraFect will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ContraFect's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ContraFect has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ContraFect performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ContraFect's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ContraFect does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare ContraFect's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ContraFect's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ContraFect's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ContraFect Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22R Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -12.79 9.81 16.36
2019-09-30 3.50 9.36 19.22
2019-06-30 4.48 9.07 19.89
2019-03-31 -6.99 8.71 21.00
2018-12-31 -37.68 8.71 21.73
2018-09-30 -48.38 9.37 19.75
2018-06-30 -45.57 9.08 19.43
2018-03-31 -28.28 9.16 17.89
2017-12-31 -15.52 9.05 16.83
2017-09-30 -10.17 10.42 16.61
2017-06-30 -19.12 10.57 17.27
2017-03-31 -25.96 10.85 20.33
2016-12-31 -28.54 11.43 20.51
2016-09-30 -36.72 9.24 20.67
2016-06-30 -31.76 9.66 17.92
2016-03-31 -29.19 9.91 15.19
2015-12-31 -25.12 10.06 13.68
2015-09-30 -22.27 10.00 11.17
2015-06-30 -33.10 9.91 10.45
2015-03-31 -34.26 8.22 7.86
2014-12-31 -34.62 8.07 6.91
2014-09-30 -40.81 6.88 6.33
2014-06-30 -28.77 6.07 6.27
2014-03-31 -24.43 6.66 6.98
2013-12-31 -23.62 6.56 7.96
2013-09-30 -18.56 6.79 9.29
2013-06-30 -20.06 6.87 9.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ContraFect has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ContraFect has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ContraFect improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ContraFect's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ContraFect has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ContraFect's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ContraFect's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ContraFect is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ContraFect's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ContraFect's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ContraFect has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ContraFect Company Filings, last reported 3 months ago.

DB:22R Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 15.54 0.00 24.18
2019-09-30 4.22 0.00 10.50
2019-06-30 9.19 0.00 14.23
2019-03-31 17.48 0.00 23.09
2018-12-31 5.54 0.00 30.45
2018-09-30 -0.70 0.00 37.60
2018-06-30 -7.16 0.00 33.29
2018-03-31 12.51 0.00 39.85
2017-12-31 31.19 0.00 46.85
2017-09-30 35.47 0.00 52.55
2017-06-30 11.09 0.00 21.71
2017-03-31 13.55 0.00 28.89
2016-12-31 19.51 0.00 35.16
2016-09-30 18.55 0.00 43.21
2016-06-30 13.77 0.00 19.09
2016-03-31 22.86 0.00 26.27
2015-12-31 30.68 0.00 32.92
2015-09-30 28.17 0.00 29.46
2015-06-30 33.13 0.00 35.26
2015-03-31 21.10 0.00 22.88
2014-12-31 25.58 0.00 27.39
2014-09-30 29.51 0.00 31.32
2014-06-30 -25.62 12.36 2.19
2014-03-31 -17.58 10.83 2.54
2013-12-31 -13.02 9.82 4.15
2013-09-30
2013-06-30 0.18 8.33 9.59
  • ContraFect has no debt.
  • ContraFect currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ContraFect has less than a year of cash runway based on current free cash flow.
  • ContraFect has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.1% each year.
X
Financial health checks
We assess ContraFect's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ContraFect has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ContraFect's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ContraFect dividends.
If you bought €2,000 of ContraFect shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ContraFect's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ContraFect's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:22R Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:22R Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ContraFect has not reported any payouts.
  • Unable to verify if ContraFect's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ContraFect's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ContraFect has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ContraFect's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ContraFect afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ContraFect has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ContraFect's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roger Pomerantz
COMPENSATION $2,015,033
AGE 62
TENURE AS CEO 1 years
CEO Bio

Dr. Roger James Pomerantz, M.D., F.A.C.P., has been Chairman and Chief Executive Officer of ContraFect Corporation since April 2, 2019 and has been its President. Dr. Pomerantz serves as Chairman of the Board at Silicon Therapeutics LLC, since July 2019. He serves as Chairman of CollPlant Biotechnologies Ltd. since February 10, 2020. He served as Venture Partner of Flagship Pioneering (formerly known as Flagship Ventures) from 2014 to 2019. He joined the Flagship Pioneering in 14th July 2014. He served as a senior partner at the Flagship Pioneering. Dr. Pomerantz focused on providing strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. Dr. Pomerantz had been the Chief Executive Officer and President of Seres Therapeutics, Inc. (formerly, Seres Health, Inc.) since June 2014 until January 15, 2018. He is the Chairman of Scientific Advisory Board at Aridis Pharmaceuticals, Inc. He has been the President of Tibotec-Virco NV since September 2005. Dr. Pomerantz serves as the President of Janssen R&D Ireland. Dr. Pomerantz served as Senior Vice President of Johnson and Johnson, Inc. From January 2011 to September 2013, he served as Senior Vice President and Worldwide Head of Licensing and Acquisitions at Merck & Co., Inc., where he oversaw licensing and acquisitions for Merck Research Laboratories, the research and development division of Merck. He was Global Franchise Head of Infectious Diseases and Senior Vice President at Merck Research Laboratories, where he oversaw pharmaceutical development and discovery of antibiotics, antivirals, antifungals and antiparasitic agents. Dr. Pomerantz has extensive academic and clinical experience, as well as knowledge in the pharmaceutical industry. Prior to joining Merck, he served as the Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He was responsible for anti-infective agents worldwide. He joined Johnson & Johnson in August 2005 as the President of Tibotec Pharmaceuticals, Inc. (now Janssen Therapeutics). He served as the President of Janssen Infectious Diseases-Diagnostics BVBA since September 1, 2005. He served as Chief of Infectious Diseases and the Founding Director and Chairman of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He was a Professor of Medicine, Biochemistry and Molecular Pharmacology at Thomas Jefferson University and Medical School. He has been Director of Intec Pharma Ltd. since March 22, 2018. He was Vice Chairman of ContraFect Corporation from May 2014 to April 2, 2019 and has been its Director since April 2014. He has been the Chair of Scientific Advisory Board at Novira Therapeutics, Inc. since August 26, 2014. He served as a Director of Rubius Therapeutics, Inc. from December 2014 until June 2019. He serves as a Member of Scientific Advisory Board at BSI Healthcapital SA. He served as a Director of Evelo Therapeutics, Inc. until May 31, 2016. He had been the Chairman of the Board of Seres Therapeutics, Inc. since November 21, 2013 until December, 2019 and serves as its Advisor. He has developed twelve small and large molecule drugs approved world-wide in critical human diseases, including HIV, HCV, CMV, C. difficile and multi-drug resistant tuberculosis. He is Board Certified in both Internal Medicine and Infectious Diseases. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute at M.I.T., in the laboratory of Nobel Laureate, Dr. David Baltimore. He completed his Internal Medicine internship and residency training and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (MGH) and served as the Chief Medical Resident at MGH. He served as Chief Resident at Massachusetts General Hospital. He received his B.A. in Biochemistry from the Johns Hopkins University and his M.D. from the Johns Hopkins School of Medicine. He received Post-Graduate Training from the Massachusetts General Hospital, Harvard Medical School and M.I.T.

CEO Compensation
  • Roger's compensation has increased whilst company is loss making.
  • Roger's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ContraFect management team in years:

3.3
Average Tenure
55.5
Average Age
  • The tenure for the ContraFect management team is about average.
Management Team

Roger Pomerantz

TITLE
Chairman
COMPENSATION
$2M
AGE
62
TENURE
1 yrs

Natalie Bogdanos

TITLE
General Counsel
COMPENSATION
$683K
AGE
50
TENURE
5.7 yrs

Cara Cassino

TITLE
Chief Medical Officer and Executive VP of Research & Development
COMPENSATION
$932K
AGE
57
TENURE
4.5 yrs

Mike Messinger

TITLE
Chief Financial Officer
COMPENSATION
$616K
AGE
44
TENURE
1.4 yrs

Nancy Dong

TITLE
Vice President of Finance & Administration
COMPENSATION
$482K
AGE
54
TENURE
3.1 yrs

Mike Wittekind

TITLE
Consultant
COMPENSATION
$794K
AGE
64
TENURE
3.5 yrs
Board of Directors Tenure

Average tenure and age of the ContraFect board of directors in years:

5.5
Average Tenure
66.5
Average Age
  • The tenure for the ContraFect board of directors is about average.
Board of Directors

Roger Pomerantz

TITLE
Chairman
COMPENSATION
$2M
AGE
62
TENURE
1 yrs

Steve Gilman

TITLE
Vice Chairman
COMPENSATION
$551K
AGE
66
TENURE
1 yrs

Vince Fischetti

TITLE
Chairman of Scientific Advisory Board

Sol Barer

TITLE
Lead Independent Director
COMPENSATION
$87K
AGE
72
TENURE
4.9 yrs

David Low

TITLE
Independent Director
COMPENSATION
$75K
AGE
60
TENURE
6 yrs

Michael Otto

TITLE
Independent Director
COMPENSATION
$73K
AGE
70
TENURE
6 yrs

Peter Palese

TITLE
Member of Scientific Advisory Board

Adolfo Garcia-Sastre

TITLE
Member of Scientific Advisory Board

Cary Sucoff

TITLE
Independent Director
COMPENSATION
$62K
AGE
67
TENURE
9.9 yrs

Leon Smith

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Dec 19 Buy Michael Messinger Individual 13. Dec 19 13. Dec 19 500 €3.33 €1,663
16. Dec 19 Buy Cary Sucoff Individual 13. Dec 19 13. Dec 19 5,000 €3.51 €17,531
16. Dec 19 Buy David Low Individual 13. Dec 19 13. Dec 19 30,000 €3.87 €115,971
X
Management checks
We assess ContraFect's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ContraFect has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Details
Name: ContraFect Corporation
22R
Exchange: DB
Founded: 2008
$77,546,402
15,332,042
Website: http://www.contrafect.com
Address: ContraFect Corporation
28 Wells Avenue,
3rd Floor,
Yonkers,
New York, 10701,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CFRX Common Stock Nasdaq Capital Market US USD 15. Sep 2014
DB 22R Common Stock Deutsche Boerse AG DE EUR 15. Sep 2014
Number of employees
Current staff
Staff numbers
24
ContraFect employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:11
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.